The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Open accessThe DOI matches its Crossref record; 335 of the 339 references it cites were found in a registry or an index.
Abstract
Transporter-mediated drug resistance is a major obstacle in anticancer drug delivery and a key reason for cancer drug therapy failure. Membrane solute carrier (SLC) transporters play a crucial role in the cellular uptake of drugs. The expression and function of the SLC transporters can be down-regulated in cancer cells, which limits the uptake of drugs into the tumor cells, resulting in the inefficiency of the drug therapy. In this review, we summarize the current understanding of low-SLC-transporter-expression-mediated drug resistance in different types of cancers. Recent advances in SLC-transporter-targeting strategies include the development of transporter-utilizing prodrugs and nanocarriers and the modulation of SLC transporter expression in cancer cells. These strategies will play an important role in the future development of anticancer drug therapies by enabling the efficient delivery of drugs into cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Reduced drug influx is a common mechanism of resistance, often resulting from decreased expression of transporters responsible for drug uptake, such as membrane solute carrier (SLC) family proteins [43].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Cancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 5,689
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.035600 · Cited by 3,665
BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
(1989) · PubMed · Cited by 3,343
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Mammalian ABC Transporters in Health and Disease
Borst, P., & Elferink, R. O. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.102301.093055 · Cited by 1,571
The SLC2 (GLUT) family of membrane transporters
Mueckler, M., & Thorens, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.001 · Cited by 1,328
The human ATP-binding cassette (ABC) transporter superfamily
Dean, M., Hamon, Y., & Chimini, G. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31588-1 · Cited by 1,302
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229
Nuclear Receptors, RXR, and the Big Bang
Evans, R. M., & Mangelsdorf, D. J. (2014) · Cell · doi:10.1016/j.cell.2014.03.012 · Cited by 1,200
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
Semenza, G. L. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104720 · Cited by 1,159
Role of amino acid transport and countertransport in nutrition and metabolism.
Christensen, H. N. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.1.43 · Cited by 1,099
Facilitative glucose transporters
MUECKLER, M. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb18550.x · Cited by 1,093
Halestrap, A. P., & Meredith, D. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1067-2 · Cited by 1,058
Integration of Oxygen Signaling at the Consensus HRE
Wenger, R. H., Stiehl, D. P., & Camenisch, G. (2005) · Science's STKE · doi:10.1126/stke.3062005re12 · Cited by 1,032
Glutamine reliance in cell metabolism
Yoo, H. C., Yu, Y. C., Sung, Y., & Han, J. M. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00504-8 · Cited by 1,021
Hagenbuch, B., & Meier, P. J. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1168-y · Cited by 1,019
ABC transporters in cancer: more than just drug efflux pumps
Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2789 · Cited by 1,018
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Ullah, M. S., Davies, A. J., & Halestrap, A. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511397200 · Cited by 890
Qiu, A., Jansen, M., Sakaris, A., Min, S. H., Chattopadhyay, S., Tsai, E., Sandoval, C., Zhao, R., Akabas, M. H., & Goldman, I. D. (2006) · Cell · doi:10.1016/j.cell.2006.09.041 · Cited by 847
Cellular pharmacology of gemcitabine
Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj941 · Cited by 842
Revisiting the Warburg effect: historical dogma versus current understanding
Vaupel, P., & Multhoff, G. (2021) · The Journal of Physiology · doi:10.1113/jp278810 · Cited by 830
Thorens, B., Sarkar, H. K., Kaback, H. R., & Lodish, H. F. (1988) · Cell · doi:10.1016/0092-8674(88)90051-7 · Cited by 786
Regulation of glut1 mRNA by Hypoxia-inducible Factor-1
Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., & Maity, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010144200 · Cited by 771
The SLC16 gene family – Structure, role and regulation in health and disease
Halestrap, A. P. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.05.003 · Cited by 763
The Role of Orphan Nuclear Receptors in the Regulation of Cholesterol Homeostasis
Repa, J. J., & Mangelsdorf, D. J. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.459 · Cited by 759
Identification of an Intestinal Heme Transporter
Shayeghi, M., Latunde-Dada, G. O., Oakhill, J. S., Laftah, A. H., Takeuchi, K., Halliday, N., Khan, Y., Warley, A., McCann, F. E., Hider, R. C., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.025 · Cited by 755
Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond
Ganapathy, V., Thangaraju, M., & Prasad, P. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.005 · Cited by 710
Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
Chronic inflammation and cancer.
Shacter, E. B., & Weitzman, S. A. (2002) · PubMed · Cited by 694
Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime?
Fuchs, B. C., & Bode, B. P. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.005 · Cited by 680
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation
Schiliro, C., & Firestein, B. L. (2021) · Cells · doi:10.3390/cells10051056 · Cited by 615
Discovery of the ergothioneine transporter
Gründemann, D., Harlfinger, S., Golz, S., Geerts, A., Lazar, A., Berkels, R., Jung, N., Rubbert, A., & Schömig, E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408624102 · Cited by 608
Biochemical Characterization of the Human Copper Transporter Ctr1
Lee, J., Peña, M. M. O., Nose, Y., & Thiele, D. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104728200 · Cited by 608
The Clinical Relevance of Cancer Cell Lines
Gillet, J.-P., Varma, S., & Gottesman, M. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt007 · Cited by 599
DIMMER, K.-S., Friedrich, B., Lang, F. J. W., Deitmer, J. W., & Bröer, S. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3500219 · Cited by 577
A human transporter protein that mediates the final excretion step for toxic organic cations
Otsuka, M., Matsumoto, T., Morimoto, R., Arioka, S., Omote, H., & Moriyama, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506483102 · Cited by 571
The SLC22 drug transporter family
Koepsell, H., & Endou, H. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1089-9 · Cited by 525
Glucose transporters in cancer – from tumor cells to the tumor microenvironment
Ancey, P., Contat, C., & Meylan, E. (2018) · The FEBS Journal · doi:10.1111/febs.14577 · Cited by 514
Gene Expression Levels and Immunolocalization of Organic Ion Transporters in the Human Kidney
Motohashi, H., Sakurai, Y., Saito, H., Masuda, S., Urakami, Y., Goto, M., Fukatsu, A., Ogawa, O., & Inui, K.-I. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v134866 · Cited by 508
Predicting the future burden of cancer
Bray, F., & Møller, B. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1781 · Cited by 486
STZ Transport and Cytotoxicity: Specific Enhancement in GLUT2-Expressing Cells
Schnedl, W. J., Ferber, S., Johnson, J. H., & Newgard, C. B. (1994) · Diabetes · doi:10.2337/diab.43.11.1326 · Cited by 483
Glucose transporters: expression, regulation and cancer
MEDINA, R. A., & OWEN, G. I. (2002) · Biological Research · doi:10.4067/s0716-97602002000100004 · Cited by 472
Glucose transporters: physiological and pathological roles
Navale, A. M., & Paranjape, A. N. (2016) · Biophysical Reviews · doi:10.1007/s12551-015-0186-2 · Cited by 445
The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations
Omote, H., Hiasa, M., Matsumoto, T., Otsuka, M., & Moriyama, Y. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.09.001 · Cited by 432
The Roles of Post-translational Modifications in the Context of Protein Interaction Networks
Duan, G., & Walther, D. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004049 · Cited by 430
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
Fukumoto, H., Seino, S., Imura, H., Seino, Y., Eddy, R. L., Fukushima, Y., Byers, M. G., Shows, T. B., & Bell, G. I. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5434 · Cited by 422
The concentrative nucleoside transporter family, SLC28
Gray, J. H., Owen, R. P., & Giacomini, K. M. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1107-y · Cited by 419
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., & Sparreboom, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.139 · Cited by 399
The SLC22 family with transporters of organic cations, anions and zwitterions
Koepsell, H. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.010 · Cited by 388
The SLCO (former SLC21) superfamily of transporters
Hagenbuch, B., & Stieger, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.009 · Cited by 385
A guide to plasma membrane solute carrier proteins
Pizzagalli, M. D., Bensimon, A., & Superti‐Furga, G. (2021) · The FEBS Journal · doi:10.1111/febs.15531 · Cited by 379
Carrier-mediated Transport of the Folic Acid Analogue, Methotrexate, in the L1210 Leukemia Cell
Goldman, I. D., Lichtenstein, N. S., & Oliverio, V. T. (1968) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)91984-8 · Cited by 372
Jonker, J. W., & Schinkel, A. H. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053298 · Cited by 372
Masuda, S., Terada, T., Yonezawa, A., Tanihara, Y., Kishimoto, K., Katsura, T., Ogawa, O., & Inui, K.-I. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006030205 · Cited by 371
Wu, X., Kekuda, R., Huang, W., Fei, Y.-J., Leibach, F. H., Chen, J., Conway, S. J., & Ganapathy, V. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32776 · Cited by 370
Airley, R. E., Loncaster, J. A., Davidson, S. E., Bromley, M., Roberts, S. K., Patterson, A. V., Hunter, R. D., Stratford, I. J., & West, C. (2001) · PubMed · Cited by 363
Structure of the human LAT1–4F2hc heteromeric amino acid transporter complex
Yan, R., Zhao, X., Lei, J., & Zhou, Q. (2019) · Nature · doi:10.1038/s41586-019-1011-z · Cited by 358
Hosoyamada, M., Sekine, T., Kanai, Y., & Endou, H. (1999) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1999.276.1.f122 · Cited by 358
Strategies for reversing drug resistance
Fojo, T., & Bates, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206951 · Cited by 357
The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29
Young, J. D., Yao, S. Y. M., Baldwin, J. M., Cass, C. E., & Baldwin, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.05.007 · Cited by 356
HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
Eltzschig, H. K., Abdulla, P., Hoffman, E., Hamilton, K. E., Daniels, D., Schönfeld, C., Löffler, M., Reyes, G., Duszenko, M., Karhausen, J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050177 · Cited by 351
Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human
Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060194 · Cited by 351
Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs
Howell, S. B., Safaei, R., Larson, C. A., & Sailor, M. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.063172 · Cited by 344
Sloan, J. L., & Mager, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23740 · Cited by 342
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., Garner, E., Campbell, F., Mackey, J. R., Costello, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt347 · Cited by 337
Wu, X., Huang, W., Prasad, P. D., Seth, P., Rajan, D. P., Leibach, F. H., Chen, J., Conway, S. J., & Ganapathy, V. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35056-6 · Cited by 330
Histone modifying enzymes: Structures, mechanisms, and specificities
Marmorstein, R., & Trievel, R. C. (2009) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2008.07.009 · Cited by 326
Glutamine transporters in mammalian cells and their functions in physiology and cancer
Bhutia, Y. D., & Ganapathy, V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.12.017 · Cited by 325
Molecular chess? Hallmarks of anti-cancer drug resistance
Cree, I. A., & Charlton, P. (2017) · BMC Cancer · doi:10.1186/s12885-016-2999-1 · Cited by 325
The Role of DNA Methylation and Histone Modifications in Transcriptional Regulation in Humans
Miller, J. L., & Grant, P. A. (2013) · Subcellular Biochemistry · doi:10.1007/978-94-007-4525-4_13 · Cited by 323
Koepsell, H., Schmitt, B. M., & Gorboulev, V. (2003) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/s10254-003-0017-x · Cited by 316
Jigorel, E., Le Vee, M., Boursier-Neyret, C., Parmentier, Y., & Fardel, O. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010033 · Cited by 315
Retinoid X receptors: common heterodimerization partners with distinct functions
Lefebvre, P., Benomar, Y., & Staels, B. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.009 · Cited by 309
Organic Cation Transporters in Health and Disease
Koepsell, H. (2020) · Pharmacological Reviews · doi:10.1124/pr.118.015578 · Cited by 297
Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments
Draoui, N., & Feron, O. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007724 · Cited by 296
Dresser, M. J., Leabman, M. K., & Giacomini, K. M. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200104)90:4<397::aid-jps1000>3.0.co;2-d · Cited by 290
THE CHARACTERISTICS OF THE MEMBRANE TRANSPORT OF AMETHOPTERIN AND THE NATURALLY OCCURRING FOLATES
Goldman, I. D. (1971) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1971.tb31167.x · Cited by 288
Sweet, D. H., Miller, D. S., Pritchard, J. B., Fujiwara, Y., Beier, D. R., & Nigam, S. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203803200 · Cited by 287
The roles of copper transporters in cisplatin resistance
Kuo, M. T., Chen, H. H. W., Song, I.-S., Savaraj, N., & Ishikawa, T. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9045-3 · Cited by 283
Hayer‐Zillgen, M., Brüss, M., & Bönisch, H. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704785 · Cited by 278
Three-dimensional structure of the human copper transporter hCTR1
De Feo, C. J., Aller, S. G., Siluvai, G. S., Blackburn, N. J., & Unger, V. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810286106 · Cited by 276
Godoy, A., Ulloa, V., Rodríguez, F., Reinicke, K., Yañez, A. J., García, M. D. L. A., Medina, R. A., Carrasco, M., Barberis, S., Castro, T., et al. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20606 · Cited by 270
Jiang, X., Xin, H., Ren, Q., Gu, J., Zhu, L., Du, F., Feng, C., Xie, Y., Sha, X., & Fang, X. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.094 · Cited by 270
Vee, M. L., Lecureur, V., Stieger, B., & Fardel, O. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023630 · Cited by 265
Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance
Xiao, H., Zheng, Y., Ma, L., Tian, L., & Sun, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648407 · Cited by 263
Drug specificity and intestinal membrane localization of human organic cation transporters (OCT)
Müller, J., Lips, K. S., Metzner, L., Neubert, R. H. H., Koepsell, H., & Brandsch, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.09.011 · Cited by 262
HIF-1 in cancer therapy: two decade long story of a transcription factor
Soni, S., & Padwad, Y. S. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1301680 · Cited by 251
Tsimberidou, A.-M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2861-1 · Cited by 249
Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma
Wiśniewski, J. R., Ostasiewicz, P., Duś, K., Zielińska, D. F., Gnad, F., & Mann, M. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.44 · Cited by 248
The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs
Zhang, J., Visser, F., King, K. M., Baldwin, S. A., Young, J. D., & Cass, C. E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9044-4 · Cited by 231
MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors
Birsoy, K., Wang, T., Possemato, R., Yilmaz, O. H., Koch, C. E., Chen, W. W., Hutchins, A. W., Gultekin, Y., Peterson, T. R., Carette, J. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2471 · Cited by 228
Molecular cloning and characterization of a novel liver-specific transport protein
Simonson, G. D., Vincent, A. C., Roberg, K. J., Huang, Y., & Iwanij, V. (1994) · Journal of Cell Science · doi:10.1242/jcs.107.4.1065 · Cited by 215
Post-translational modifications of transporters
Czuba, L. C., Hillgren, K. M., & Swaan, P. W. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.013 · Cited by 214
Prediction of adipose tissue: Plasma partition coefficients for structurally unrelated drugs
Poulin, P., Schoenlein, K., & Theil, F. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200104)90:4<436::aid-jps1002>3.0.co;2-p · Cited by 213
Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1
Geier, E. G., Schlessinger, A., Fan, H., Gable, J. E., Irwin, J. J., Sali, A., & Giacomini, K. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218165110 · Cited by 212
García-Manteiga, J. M., Molina‐Arcas, M., Casado, F. J., Mazo, A., & Pastor‐Anglada, M. (2003) · PubMed · Cited by 211
Organic Anion Transporter Family: Current Knowledge
Anzai, N., Kanai, Y., & Endou, H. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.crj06006x · Cited by 209
L-Type amino acid transporter 1 as a target for drug delivery
Puris, E., Gynther, M., Auriola, S., & Huttunen, K. M. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02826-8 · Cited by 205
Self-citationWesterhof, G. R., Schornagel, J. H., Kathmann, I., Jackman, A. L., Rosowsky, A., Forsch, R. A., Hynes, J. B., Boyle, F. T., Peters, G. J., & Pinedo, H. M. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10494-x · Cited by 204
Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney
Motohashi, H., & Inui, K.-I. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9465-7 · Cited by 199
Polyspecific organic cation transporters: their functions and interactions with drugs
Koepsell, H. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.05.005 · Cited by 198
Zhao, R., & Goldman, I. D. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.006 · Cited by 190
Gender-Specific and Developmental Influences on the Expression of Rat Organic Anion Transporters
Buist, S. C. N., Cherrington, N. J., Choudhuri, S., Hartley, D. P., & Klaassen, C. D. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.145 · Cited by 186
Differential Expression of Human Nucleoside Transporters in Normal and Tumor Tissue
Pennycooke, M., Chaudary, N., Shuralyova, I., Zhang, Y., & Coe, I. R. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4205 · Cited by 186
Interaction of Methotrexate with Organic-Anion Transporting Polypeptide 1A2 and Its Genetic Variants
Badagnani, I., Castro, R. A., Taylor, T. R., Brett, C. M., Huang, C. C., Stryke, D., Kawamoto, M., Johns, S. J., Ferrin, T. E., Carlson, E. J., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104364 · Cited by 184
Drug-activated nuclear receptors CAR and PXR
Honkakoski, P., Sueyoshi, T., & Negishi, M. (2003) · Annals of Medicine · doi:10.1080/07853890310008224 · Cited by 180
Pértega-Gomes, N., Vizcaíno, J. R., Miranda-Gonçalves, V., Pinheiro, C., Silva, J., Pereira, H., Monteiro, P., Henrique, R. M., Reis, R. M., Lopes, C., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-312 · Cited by 178
Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7])
Kobayashi, Y., Ohshiro, N., Sakai, R., Ohbayashi, M., Kohyama, N., & Yamamoto, T. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357055966 · Cited by 178
Mechanisms of acquired tumor drug resistance
Aleksakhina, S. N., Kashyap, A., & Imyanitov, E. N. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188310 · Cited by 177
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2
Sprowl, J. A., Ciarimboli, G., Lancaster, C. S., Giovinazzo, H., Gibson, A. A., Du, G., Janke, L. J., Cavaletti, G., Shields, A. F., & Sparreboom, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305321110 · Cited by 175
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters
Okabe, M., Szakács, G., Reimers, M. A., Suzuki, T., Hall, M. D., Abe, T., Weinstein, J. N., & Gottesman, M. M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0539 · Cited by 173
Thorens, B., Wu, Y. J., Leahy, J. L., & Weir, G. C. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115858 · Cited by 166
Choudhuri, S., Cherrington, N. J., Li, N., & Klaassen, C. D. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1337 · Cited by 164
Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Zimmerman, E. I., Hu, S., Roberts, J. L., Gibson, A. A., Orwick, S. J., Li, L., Sparreboom, A., & Baker, S. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3306 · Cited by 164
Nunez, M. I., Behrens, C., Woods, D. M., Lin, H., Suraokar, M., Kadara, H., Hofstetter, W., Kalhor, N., Lee, J. J., Franklin, W., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824de09c · Cited by 160
Che, M., Ortiz, D. F., & Arias, I. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.23.13596 · Cited by 157
Schaeffeler, E., Hellerbrand, C., Nies, A. T., Winter, S., Kruck, S., Hofmann, U., van der Kuip, H., Zanger, U. M., Koepsell, H., & Schwab, M. G. (2011) · Genome Medicine · doi:10.1186/gm298 · Cited by 157
Zhao, R., Min, S. H., Wang, Y., Campanella, E., Low, P. S., & Goldman, I. D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807665200 · Cited by 156
The human proton-coupled folate transporter: Biology and therapeutic applications to cancer
Desmoulin, S. K., Hou, Z., Gangjee, A., & Matherly, L. H. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.22020 · Cited by 155
The Relationship of Redox With Hallmarks of Cancer: The Importance of Homeostasis and Context
Xing, F., Hu, Q., Qin, Y., Xu, J., Zhang, B., Yu, X., & Wang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.862743 · Cited by 154
Vée, M. L., Gripon, P., Stieger, B., & Fardel, O. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016907 · Cited by 150
Hubeek, I., Stam, R. W., Peters, G. J., Broekhuizen, R., Meijerink, J. P. P., van Wering, E. R., Gibson, B. E. S., Creutzig, U., Zwaan, C. M., Cloos, J. J., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602881 · Cited by 150
Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A)
Terada, T., & Inui, K. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.12.008 · Cited by 146
Patra, M., Awuah, S. G., & Lippard, S. J. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b06937 · Cited by 145
Wright, J. L., Kwon, E. M., Ostrander, E. A., Montgomery, R. B., Lin, D. W., Vessella, R., Stanford, J. L., & Mostaghel, E. A. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1023 · Cited by 144
Tiwari, A., Tashiro, K., Dixit, A., Soni, A., Vogel, K., Hall, B., Shafqat, I., Slaughter, J., Param, N., Le, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.046 · Cited by 142
El Ansari, R., Craze, M. L., Miligy, I., Diez-Rodriguez, M., Nolan, C. C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0946-6 · Cited by 139
Hypoxia-inducible factor 1 (HIF-1) in cancer
Quintero, M., Mackenzie, N., & Brennan, P. A. (2004) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2004.03.008 · Cited by 139
Meyer zu Schwabedissen, H. E., Tirona, R. G., Yip, C. S., Ho, R. H., & Kim, R. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0265 · Cited by 138
Evidence for two Types of Mediation of Neutral Amino-Acid Transport in Ehrlich Cells
Oxender, D. L., & Christensen, H. N. (1963) · Nature · doi:10.1038/197765a0 · Cited by 138
What is pH regulation, and why do cancer cells need it?
Swietach, P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-09778-x · Cited by 136
Gupta, N., Miyauchi, S., Martindale, R. G., Herdman, A. V., Podolsky, R., Miyake, K., Mager, S., Prasad, P. D., Ganapathy, M. E., & Ganapathy, V. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.04.002 · Cited by 135
Younes, M., Lechago, L. V., & Lechago, J. (1996) · PubMed · Cited by 134
Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer
Lee, W., Belkhiri, A., Lockhart, A. C., Merchant, N. B., Glaeser, H., Harris, E. I., Washington, M. K., Brunt, E. M., Zaika, A., Kim, R. B., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1984 · Cited by 134
Alam, K., Crowe, A., Wang, X., Zhang, P., Ding, K., Li, L., & Yue, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030855 · Cited by 132
Zhao, R., Qiu, A., Tsai, E., Jansen, M., Akabas, M. H., & Goldman, I. D. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.045443 · Cited by 129
Distinct Mechanisms for Ctr1-mediated Copper and Cisplatin Transport
Sinani, D., Adle, D. J., Kim, H., & Lee, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703973200 · Cited by 129
Qiu, A., Min, S. H., Jansen, M., Malhotra, U., Tsai, E., Cabelof, D. C., Matherly, L. H., Zhao, R., Akabas, M. H., & Goldman, I. D. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00202.2007 · Cited by 126
Hartmann, E., Fernández, V., Moreno, V. R., Valls, J., Hernández, L., Bosch, F., Abrisqueta, P., Klapper, W., Dreyling, M. H., Hoster, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0410 · Cited by 126
Role of copper transporters in platinum resistance
Kilari, D. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.106 · Cited by 124
Functional Analysis of Organic Cation Transporter 3 Expressed in Human Placenta
Sata, R., Ohtani, H., Tsujimoto, M., Murakami, H., Koyabu, N., Nakamura, T., Uchiumi, T., Kuwano, M., Nagata, H., Tsukimori, K., et al. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086827 · Cited by 123
Taylor, S. T., Hickman, J. A., & Dive, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.1.18 · Cited by 116
Up-regulation of the amino acid transporter ATB0,+ (SLC6A14) in carcinoma of the cervix
Gupta, N., Prasad, P. D., Ghamande, S. A., Martin, P. M., Herdman, A. V., Martindale, R. G., Podolsky, R. H., Mager, S., Ganapathy, M. E., & Ganapathy, V. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.016 · Cited by 115
Landowski, C. P., Vig, B. S., Song, X., & Amidon, G. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0290 · Cited by 113
Aller, S. G., Eng, E. T., De Feo, C. J., & Unger, V. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409421200 · Cited by 112
Yokoo, S., Masuda, S., Yonezawa, A., Terada, T., Katsura, T., & Inui, K. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023168 · Cited by 112
Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy
Gou, Q., Gong, X., Jin, J., Shi, J., & Hou, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.19610 · Cited by 112
Podgórska, M., Kocbuch, K., & Pawełczyk, T. (2005) · Acta Biochimica Polonica · doi:10.18388/abp.2005_3386 · Cited by 112
Allenby, G., Janocha, R., Kazmer, S., Speck, J., Grippo, J. F., & Levin, A. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)89445-0 · Cited by 111
Siu, M. K. Y., Kong, D. S. H., Chan, H. Y., Wong, E. S. Y., Ip, P. P. C., Jiang, L., Ngan, H. Y. S., Le, X.-F., & Cheung, A. N. Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047201 · Cited by 108
Smith, K. M., Ng, A. M. L., Yao, S. Y. M., Labedz, K. A., Knaus, E. E., Wiebe, L. I., Cass, C. E., Baldwin, S. A., Chen, X., Karpinski, E., et al. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.068189 · Cited by 104
Kang, N., Jun, A. H., Bhutia, Y. D., Kannan, N., Unadkat, J. D., & Govindarajan, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.109199 · Cited by 103
SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma
Kim, Y. H., Jeong, D. C., Pak, K., Han, M.-E., Kim, J.-Y., Liangwen, L., Kim, H. J., Kim, T. W., Kim, T. H., Hyun, D. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20266 · Cited by 102
Ong, Z. Y., Chen, S., Nabavi, E., Regoutz, A., Payne, D. J., Elson, D. S., Dexter, D. T., Dunlop, I. E., & Porter, A. E. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b14851 · Cited by 102
Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
Neul, C., Schaeffeler, E., Sparreboom, A., Laufer, S., Schwab, M. G., & Nies, A. T. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.08.003 · Cited by 101
SLC31 (CTR) family of copper transporters in health and disease
Kim, H., Wu, X., & Lee, J. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.011 · Cited by 101
The aryl hydrocarbon receptor (AhR) as a drug target for cancer chemotherapy
Safe, S., Cheng, Y., & Jin, U.-H. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.01.012 · Cited by 99
Spanier, B., & Rohm, F. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170038 · Cited by 97
Expression of the nucleoside‐derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors
Farré, X., Guillén‐Gómez, E., Sánchez, L., Hardisson, D., Plaza, Y., Lloberas, J., Casado, F. J., Palacios, J., & Pastor‐Anglada, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20524 · Cited by 96
Svoboda, M., Wlcek, K., Taferner, B., Hering, S., Stieger, B., Castillo‐Tong, D. C., Zeillinger, R., Thalhammer, T., & Jäger, W. R. (2011) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.04.031 · Cited by 94
Liver X receptors and fat cell metabolism
Laurencikiene, J., & Rydén, M. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.21 · Cited by 93
Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?
Puris, E., Fricker, G., & Gynther, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03241-x · Cited by 92
Self-citationInazu, M., Takeda, H., & Matsumiya, T. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01566.x · Cited by 91
Pochini, L., Galluccio, M., Scalise, M., Console, L., & Indiveri, C. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218812821 · Cited by 91
Wiśniewski, J. R., Duś-Szachniewicz, K., Ostasiewicz, P., Ziółkowski, P., Rakus, D., & Mann, M. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00523 · Cited by 90
Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-dependent kinases
Çetinkaya, I., Ciarimboli, G., Yalçinkaya, G., Mehrens, T., Velić, A., Hirsch, J. R., Gorboulev, V., Koepsell, H., & Schlatter, E. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00251.2002 · Cited by 90
Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
Schulte, R. R., & Ho, R. H. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.114314 · Cited by 89
Regulation of RXR-RAR Heterodimers by RXR- and RAR-Specific Ligands and Their Combinations
le Maire, A., Teyssier, C., Balaguer, P., Bourguet, W., & Germain, P. (2019) · Cells · doi:10.3390/cells8111392 · Cited by 88
Regulation of the human organic cation transporter hOCT1
Ciarimboli, G., Struwe, K., Arndt, P., Gorboulev, V., Koepsell, H., Schlatter, E., & Hirsch, J. R. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20081 · Cited by 87
Shao, K., Ding, N., Huang, S., Ren, S., Zhang, Y., Kuang, Y., Guo, Y., Ma, H., An, S., Li, Y., et al. (2014) · ACS Nano · doi:10.1021/nn406285x · Cited by 86
Maimaiti, M., Sakamoto, S., Yamada, Y., Sugiura, M., Rii, J., Takeuchi, N., Imamura, Y., Furihata, T., Ando, K., Higuchi, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58136-x · Cited by 86
Cheng, Y., Vapurcuyan, A., Shahidullah, M., Aleksunes, L. M., & Pelis, R. M. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042036 · Cited by 85
Chen, C., Hsu, E., Lin, K., Tu, P., Chang, H.-W., Lin, C.-H., Chen, Y.-J., Gu, D.-L., Lin, C.-H., Wu, J.-Y., et al. (2010) · Hepatology · doi:10.1002/hep.23847 · Cited by 85
Substrate recognition and translocation by polyspecific organic cation transporters
Koepsell, H. (2011) · Biological Chemistry · doi:10.1515/bc.2011.009 · Cited by 85
Ballestero, M. R., Monte, M. J., Briz, Ó., Jimenez, F., Martin, F. G.-S., & Marı́n, J. J. G. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.007 · Cited by 84
Liver X Receptor α and Farnesoid X Receptor Are Major Transcriptional Regulators of OATP1B1
zu Schwabedissen, H. E. M., Böttcher, K., Chaudhry, A. S., Kroemer, H. K., Schuetz, E. G., & Kim, R. B. (2010) · Hepatology · doi:10.1002/hep.23876 · Cited by 84
Chai, Y. J., Yi, J. W., Oh, S. W., Kim, Y. A., Yi, K. H., Kim, J. H., & Lee, K. E. (2016) · Surgery · doi:10.1016/j.surg.2016.04.050 · Cited by 83
Shen, H., Liu, T., Morse, B. L., Zhao, Y., Zhang, Y., Qiu, X., Chen, C., Lewin, A. C., Wang, X., Liu, G., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062364 · Cited by 82
Huang, Q. Q., Harvey, C. M., Paterson, A. R., Cass, C. E., & Young, J. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80769-8 · Cited by 82
Deuschle, U., Schüler, J., Schulz, A., Schlüter, T., Kinzel, O., Abel, U., & Kremoser, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043044 · Cited by 81
Xie, J., Xia, L., Xiang, W., He, W., Yin, H., Wang, F., Gao, T., Qi, W., Yang, Z., Yang, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918845117 · Cited by 81
Venishetty, V. K., Samala, R., Komuravelli, R., Kuncha, M., Sistla, R., & Diwan, P. V. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.08.004 · Cited by 81
Cited by
Understanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 167
Hallmarks of cancer resistance
Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · iScience · doi:10.1016/j.isci.2024.109979 · Cited by 149
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Reduced drug influx is a common mechanism of resistance, often resulting from decreased expression of transporters responsible for drug uptake, such as membrane solute carrier (SLC) family proteins [43].”
Pu, J., Yuan, K., Tao, J., Qin, Y., Li, Y., Fu, J., Zhong, L., Zhou, H., Tang, Z., Li, L., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02567-3 · Cited by 77
Barathan, M., Zulpa, A. K., Ng, S. L., Lokanathan, Y., Ng, M. H., & Law, J. X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137470 · Cited by 55
Metadata
- Authors
- Puris, E., Fricker, G., & Gynther, M.
- Affiliations
- Heidelberg University (DE)
- Corresponding author
- Gynther, Mikko
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2023-01-21
- Volume
- 15
- Issue
- 2
- Pages
- 364
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9966068
- OpenAlex
- W4317733597
- Cited by
- 58
- References
- 339
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 19 · 2023: 3
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- solute carrier transporters, anticancer drug delivery, drug resistance, cancer cells, drug uptake, nanocarriers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.